AXSM AXSOME THERAPEUTICS

Axsome Therapeutics to Participate in Investor Conferences in September

Axsome Therapeutics to Participate in Investor Conferences in September

Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York

Wells Fargo Healthcare Conference on September 5 in Boston

Baird 2024 Global Healthcare Conference on September 11 in New York

Cantor Global Healthcare Conference on September 18 in New York

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will participate in four investor conferences in September:

  • Morgan Stanley 22nd Annual Global Healthcare Conference

    The Company will present on Wednesday, September 4, 2024 at 4:50 p.m. ET in New York, NY
  • 2024 Wells Fargo Healthcare Conference

    The Company will participate in investor meetings on Thursday, September 5, 2024 in Boston, MA
  • Baird 2024 Global Healthcare Conference

    The Company will present on Wednesday, September 11, 2024 at 8:30 a.m. ET in New York, NY
  • 2024 Cantor Global Healthcare Conference

    The Company will present on Wednesday, September 18, 2024 at 9:45 a.m. ET in New York, NY

Live webcasts of the presentations at the Morgan Stanley and Cantor conferences can be accessed on the Investors page of the Company’s website at Replays of the webcasts will be available for approximately 30 days following each event.

About Axsome Therapeutics

Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company’s website at

Investors:

Mark Jacobson

Chief Operating Officer

(212) 332-3243

Media:

Darren Opland

Director, Corporate Communications

(929) 837-1065



EN
27/08/2024

Underlying

AXSMAXSOME THERAPEUTICS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AXSOME THERAPEUTICS

 PRESS RELEASE
Free
AXSM AXSOME THERAPEU...

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and ...

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® 2Q 2025 net product sales of $119.6 million, representing growth of 84% year-over-year and 24% sequentially SUNOSI® 2Q 2025 net product revenue of $30.0 million, representing growth of 35% year-over-year and 19% sequentially SYMBRAVO® launched June 10th, with 2Q 2025 net product sales of $0.4 million AUVELITY® market access expanded by 28 million...

August 4, 2025 1 EN
 PRESS RELEASE
Free
AXSM AXSOME THERAPEU...

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing ...

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses Presentations by expert clinicians and key opinion leaders Company to webcast its R&D Day event today at 11:00 AM Eastern NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorder...

July 21, 2025 1 EN
 PRESS RELEASE
Free
AXSM AXSOME THERAPEU...

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, along with the rest of the management team, and other Axsome team members, will ring the opening bell of the NASDAQ Stock Market today, Monday, July 21, 2025, in connection with its Frontiers in Brain Health R&D Day event being held today. Herriot Tabute...

July 21, 2025 1 EN
 PRESS RELEASE
Free
AXSM AXSOME THERAPEU...

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on...

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live c...

July 9, 2025 1 EN
 PRESS RELEASE
Free
AXSM AXSOME THERAPEU...

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcomin...

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will host its Frontiers in Brain Health R&D Day on July 21, 2025, starting at 11:00 a.m. Eastern Time in New York City. The event will highlight Axsome’s singular, innovative late-stage CNS pipeline. At the event, physician key opinion leaders ...

July 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch